Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108099
Title:
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.
Authors:
Lind, Michael J; Margison, Jennifer M; Cerny, T; Thatcher, Nick; Wilkinson, Peter M
Abstract:
The pharmacokinetics of intravenous ifosfamide were determined in 16 patients with carcinoma of the bronchus. In all 25% (4) of these patients were obese (i.e. greater than 20% over their ideal body weight). The terminal elimination half-life (t1/2 beta) was found to be higher in the obese group than in the control group (6.36 h, range 5.77-7.45 h) vs 4.95 h, range 1.82-6.48 h) (P less than 0.05). This prolongation of the elimination half-life was due to an increased volume of distribution (Vd beta) in the obese group (42.81 1, range 35.49-51.90 l) vs 33.70 l range (17.76-50.62 l) (P less than 0.05). There was therefore no significant difference in total plasma clearance between the obese and normal groups. No correlation of ifosfamide plasma half-life was observed with total body weight (TBW) or ideal body weight (IBW). However, a significant positive correlation was observed between the percentage of IBW and plasma half-life. A strong positive correlation was observed between IBW and the plasma clearance of ifosfamide. The Vd beta correlated with both TBW and the percentage of IBW, but not with IBW itself. When Vd beta was normalised for IBW, there was a strong positive correlation with the percentage of IBW, suggesting that ifosfamide distribution into the TBW is higher than that into the IBW.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, U.K.
Citation:
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. 1989, 25 (2):139-42 Cancer Chemother. Pharmacol.
Journal:
Cancer Chemotherapy and Pharmacology
Issue Date:
1989
URI:
http://hdl.handle.net/10541/108099
DOI:
10.1007/BF00692355
PubMed ID:
2557169
Type:
Article
Language:
en
ISSN:
0344-5704
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLind, Michael Jen
dc.contributor.authorMargison, Jennifer Men
dc.contributor.authorCerny, Ten
dc.contributor.authorThatcher, Nicken
dc.contributor.authorWilkinson, Peter Men
dc.date.accessioned2010-07-21T15:11:15Z-
dc.date.available2010-07-21T15:11:15Z-
dc.date.issued1989-
dc.identifier.citationProlongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. 1989, 25 (2):139-42 Cancer Chemother. Pharmacol.en
dc.identifier.issn0344-5704-
dc.identifier.pmid2557169-
dc.identifier.doi10.1007/BF00692355-
dc.identifier.urihttp://hdl.handle.net/10541/108099-
dc.description.abstractThe pharmacokinetics of intravenous ifosfamide were determined in 16 patients with carcinoma of the bronchus. In all 25% (4) of these patients were obese (i.e. greater than 20% over their ideal body weight). The terminal elimination half-life (t1/2 beta) was found to be higher in the obese group than in the control group (6.36 h, range 5.77-7.45 h) vs 4.95 h, range 1.82-6.48 h) (P less than 0.05). This prolongation of the elimination half-life was due to an increased volume of distribution (Vd beta) in the obese group (42.81 1, range 35.49-51.90 l) vs 33.70 l range (17.76-50.62 l) (P less than 0.05). There was therefore no significant difference in total plasma clearance between the obese and normal groups. No correlation of ifosfamide plasma half-life was observed with total body weight (TBW) or ideal body weight (IBW). However, a significant positive correlation was observed between the percentage of IBW and plasma half-life. A strong positive correlation was observed between IBW and the plasma clearance of ifosfamide. The Vd beta correlated with both TBW and the percentage of IBW, but not with IBW itself. When Vd beta was normalised for IBW, there was a strong positive correlation with the percentage of IBW, suggesting that ifosfamide distribution into the TBW is higher than that into the IBW.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshChromatography, High Pressure Liquid-
dc.subject.meshHalf-Life-
dc.subject.meshHumans-
dc.subject.meshIfosfamide-
dc.subject.meshLung Neoplasms-
dc.subject.meshMesna-
dc.subject.meshMiddle Aged-
dc.subject.meshObesity-
dc.subject.meshTime Factors-
dc.subject.meshTissue Distribution-
dc.titleProlongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, U.K.en
dc.identifier.journalCancer Chemotherapy and Pharmacologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.